| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,382 |
14,417 |
$663K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,767 |
6,568 |
$389K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,082 |
4,807 |
$348K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,901 |
6,489 |
$324K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,899 |
1,839 |
$163K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,573 |
4,371 |
$146K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,067 |
3,871 |
$99K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
985 |
955 |
$94K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,872 |
2,701 |
$41K |
| 71046 |
Radiologic examination, chest; 2 views |
2,507 |
2,374 |
$27K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
339 |
332 |
$20K |
| 99000 |
|
1,004 |
989 |
$13K |
| 81025 |
|
1,916 |
1,826 |
$12K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
435 |
425 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,344 |
2,277 |
$9K |
| 99201 |
|
310 |
298 |
$9K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,208 |
1,161 |
$7K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
889 |
860 |
$6K |
| 81001 |
|
2,290 |
2,169 |
$6K |
| 80053 |
Comprehensive metabolic panel |
474 |
453 |
$4K |
| 93000 |
|
311 |
296 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
80 |
79 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
78 |
77 |
$3K |
| 87081 |
|
655 |
643 |
$2K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
14 |
13 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
304 |
143 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
57 |
54 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
665 |
636 |
$1K |
| 84484 |
|
78 |
71 |
$874.23 |
| 85027 |
|
156 |
151 |
$844.12 |
| 81003 |
|
603 |
577 |
$787.75 |
| 83690 |
|
122 |
112 |
$700.27 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
48 |
45 |
$527.62 |
| 87210 |
|
79 |
77 |
$349.83 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
25 |
24 |
$288.76 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
101 |
90 |
$135.99 |
| 85379 |
|
12 |
12 |
$107.68 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$99.03 |
| 85007 |
|
12 |
12 |
$47.55 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
524 |
463 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
12 |
12 |
$0.00 |